All Posts Tagged With: "WYE"
(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(ABT) Abbott Laboratories Outperforms & Raises
Abbott Laboratories (ABT) reported third quarter earnings of 92 cents per share, 2 cents above the Zacks Consensus Estimate of 90 cents. Results were above the company’s guidance of 88 – 90 cents. Earnings increased 16.5% from the year-ago period. Total revenues grew 3.5%...
16Oct2009 | vitalstocks | 0 comments | Continued(NKTR) Nektar Therapeutics Presents Favorable Phase II Trial Data
Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management’s 20th Annual Clinical Meeting in Phoenix, AZ. The drug...
13Oct2009 | vitalstocks | 0 comments | Continued(NVS) Novartis Acquires Antibiotic Rights
Today, Novartis (NVS) acquired exclusive worldwide rights to PTK 0796, a broad spectrum antibiotic from a privately held company, Paratek Pharmaceuticals. The drug is meant for the treatment of infections caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus...
9Oct2009 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca and Nektar Therapeutics Deal to Add Value
Recently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation, the latter, in early stage...
3Oct2009 | vitalstocks | 0 comments | Continued(T) Top Income Equity Funds – Mutual Fund Commentary
Today we are featuring top-performing “Income” equity mutual funds, which primarily invest in equity securities of companies in search of income. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Income Equity Funds. 3 Solid Samples Parnassus...
24Sep2009 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Signs Licensing Deal With Nektar Therapeutics
Yesterday, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation, the latter, in early stage...
22Sep2009 | vitalstocks | 0 comments | Continued(WYE) Wyeth Pharmaceuticals Reports Positive Drug Data
Yesterday, Wyeth Pharmaceuticals, a division of Wyeth (WYE), announced data from a placebo-controlled late-stage study of its drug candidate bazedoxifene 20 mg in postmenopausal women with osteoporosis. The results indicated that women who took bazedoxifene had a lower risk of...
16Sep2009 | vitalstocks | 0 comments | Continued(THRX) Theravance Earns FDA Approval for Skin Infection Drug
In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. Vibativ, jointly developed with Japan’s...
16Sep2009 | vitalstocks | 0 comments | Continued(FRX) Forest Laboratories Presents Encouraging Data
We are pleased to hear that Forest Laboratories (FRX) presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia [CAP] in hospitalized patients. The company presented new data from two multicenter studies – FOCUS 1 and...
14Sep2009 | vitalstocks | 0 comments | Continued(SLXP) Salix Pharmaceuticals Gets Marketing Approval
Salix Pharmaceuticals, Ltd. (SLXP) received positive news yesterday when the U.S. Food and Drug Administration (FDA) granted marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. Metozolv ODT received approval for the relief of symptoms...
9Sep2009 | vitalstocks | 0 comments | Continued(JNJ) Johnson & Johnson Responds to FDA Questions on Antibiotic Drug Trials
We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial of ceftobiprole, a broad-spectrum...
2Sep2009 | vitalstocks | 0 comments | Continued(ACH) Top Income Equity Funds – Mutual Fund Commentary
Today we are featuring top-performing “Income” equity mutual funds, which primarily invest in equity securities of companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Income Equity Funds. 3 Strong Samples Azzad Ethical Income...
26Aug2009 | vitalstocks | 0 comments | Continued(LGND) Ligand Pharmaceuticals to Buy Neurogen
Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth...
25Aug2009 | vitalstocks | 0 comments | Continued(GSK) Pharma Majors to Gain from India
All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on...
19Aug2009 | vitalstocks | 0 comments | Continued(LLY) Lilly Discontinues Arzoxifene Trials
Yesterday, Eli Lilly and Company (LLY) announced that it will not seek approval from the U.S. Food and Drug Administration (FDA) for its phase III pipeline candidate, arzoxifene, which is being developed for the prevention and treatment of osteoporosis in postmenopausal women...
19Aug2009 | vitalstocks | 0 comments | Continued(WYE) FDA’s Delay Cramps Wyeth
The delay in the US Food and Drug Administration’s (FDA) decision to approve Wyeth’s (WYE) Prevnar 13 (PV13) vaccine is a major blow to the company. Wyeth had filed for FDA approval of the pediatric vaccine PV13 on March 31, 2009. In May 2009, the FDA granted the New Drug...
14Aug2009 | vitalstocks | 0 comments | Continued(PFE) Pharmaceuticals & Biotech – Zacks Analyst Interviews
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and...
9Jun2009 | vitalstocks | 0 comments | Continued(PFE) Pharmaceuticals & Biotech – Industry Outlook
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and...
8Jun2009 | vitalstocks | 0 comments | Continued(MRK) Drug Companies: A Powerhouse of Profits
by The Investment U Research Team A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost...
9May2009 | InvestmentU | 0 comments | Continued(WYE) Biotech Industry – Industry Outlook
OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather...
13Mar2009 | vitalstocks | 0 comments | Continued